Ayasha

Ayasha is a biotechnology company focused on advancing women's health by developing novel therapies for menopause and ovarian aging. Launched as a joint venture between Bayer and OrbiMed, the company aims to address the significant unmet medical needs associated with the decline of ovarian function. Ayasha leverages insights into the biological mechanisms of reproductive aging to create treatments that improve the quality of life for women transitioning through menopause. The company operates in a relatively underserved area of the life sciences, targeting the underlying causes of hormonal shifts rather than just managing symptoms. By combining Bayer's expertise in women's healthcare with OrbiMed's investment and development capabilities, Ayasha is positioned to pioneer new standards of care in reproductive longevity.